ライフサイエンスコーパス: cardiac amyloidosis

1 ility of (18)F-florbetaben PET in diagnosing cardiac amyloidosis.

2 ent determinant of myocardial dysfunction in cardiac amyloidosis.

3 ients with symptomatic heart failure from AL cardiac amyloidosis.

4 with worse survival among patients with ATTR cardiac amyloidosis.

5 andard for diagnosis and characterization of cardiac amyloidosis.

6 9m PYP cardiac imaging for detection of ATTR cardiac amyloidosis.

7 ty in patients with amyloid light-chain (AL) cardiac amyloidosis.

8 ility to overcome poor prognosis of advanced cardiac amyloidosis.

9 ned reliably by PSIR and represents advanced cardiac amyloidosis.

10 protinin was found to be useful in detecting cardiac amyloidosis.

11 e curve 0.992, P<0.0001 for identifying ATTR cardiac amyloidosis.

12 endent validation set comprising 41 cases of cardiac amyloidosis.

13 cy of intracardiac thrombosis was present in cardiac amyloidosis.

14 cement CMR was performed in 30 patients with cardiac amyloidosis.

15 n models that predict the log-odds of having cardiac amyloidosis.

16 dial biopsy because of clinical suspicion of cardiac amyloidosis.

17 out the prognostic value of CV-IB in primary cardiac amyloidosis.

18 There is no muscle blood vessel or cardiac amyloidosis.

19 as both sporadic inclusion body myositis and cardiac amyloidosis.

20 be a useful predictor of clinical outcome in cardiac amyloidosis.

21 edictor of clinical outcome in patients with cardiac amyloidosis.

22 myocardial performance in the assessment of cardiac amyloidosis.

23 ause of heart failure in Afro-Caribbeans was cardiac amyloidosis (11.4%).

24 TTR cardiac amyloidosis and 50 with non-ATTR cardiac amyloidosis [34 with AL amyloidosis and 16 with

25 A total of 116 autopsy or explanted cases of cardiac amyloidosis (55 AL and 61 other type) were ident

26 In patients with suspected cardiac amyloidosis, a combination of noninvasive parame

27 Importance: Transthyretin cardiac amyloidosis (also known as ATTR cardiac amyloido

28 nsible for the increased frequency of senile cardiac amyloidosis among blacks.

29 P imaging of 171 participants (121 with ATTR cardiac amyloidosis and 50 with non-ATTR cardiac amyloid

30 ambda II germ-line genes was associated with cardiac amyloidosis and affected survival adversely.

31 in which 229 participants were evaluated for cardiac amyloidosis and also underwent Tc 99m PYP cardia

32 78 whites over 60 years of age with isolated cardiac amyloidosis and from two control groups (228 cas

33 ccurately identify and differentiate between cardiac amyloidosis and hypertensive heart disease.

34 ardiac imaging as a diagnostic tool for ATTR cardiac amyloidosis and its association with survival in

35 P cardiac imaging distinguishes AL from ATTR cardiac amyloidosis and may be a simple, widely availabl

36 espective of genotype) from patients with AL cardiac amyloidosis and patients with nonamyloid heart f

37 HDM is feasible in patients with cardiac amyloidosis, and achievement of HR and organ res

38 approaches to the diagnosis and treatment of cardiac amyloidosis are discussed, with particular refer

39 d 216 patients with histologically confirmed cardiac amyloidosis at a single center with electrocardi

40 Transthyretin cardiac amyloidosis (ATTR) is an underrecognized cause o

41 hese conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly being diagn

42 Wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasingly recognized

43 is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying r

44 ) cardiac imaging noninvasively detects ATTR cardiac amyloidosis, but the accuracy of this technique

45 myloid deposition in the heart, diagnosis of cardiac amyloidosis (CA) based on these conventional tec

46 Differentiation of cardiac amyloidosis (CA) from other causes of concentric

47 meters has been suggested for distinguishing cardiac amyloidosis (CA) from other causes of myocardial

48 unoglobulin amyloid light-chain (AL)-related cardiac amyloidosis (CA) has a worse prognosis than eith

49 Cardiac amyloidosis can be diagnostically challenging.

50 atic approach to the evaluation of suspected cardiac amyloidosis can impact the prognosis of patients

51 Cardiac amyloidosis can present as angina pectoris assoc

52 Clinical clues to promote recognition of cardiac amyloidosis, cardiac sarcoidosis, and cardiac he

53 which tailored interventions are available: cardiac amyloidosis, cardiac sarcoidosis, and cardiac he

54 Amyloid involvement of the heart (cardiac amyloidosis) carries the worst prognosis of any

55 In cardiac amyloidosis, CMR shows a characteristic pattern

56 ptal thickness is >1.98 cm, the diagnosis of cardiac amyloidosis could be made with a sensitivity of

57 Among patients with cardiac amyloidosis, CV-IB at the LV posterior wall is a

58 ardiogram were associated with biopsy-proven cardiac amyloidosis (each p < 0.01).

59 l presentation, diagnosis, and management of cardiac amyloidosis, focusing on recent important develo

60 at may be associated with thromboembolism in cardiac amyloidosis have not been defined.

61 ognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and

62 magnetic resonance findings were of definite cardiac amyloidosis in 2, but could be explained solely

63 ging have resulted in greater recognition of cardiac amyloidosis in everyday clinical practice, but t

64 erformed at 3 academic specialty centers for cardiac amyloidosis in the United States in which 229 pa

65 Light chain cardiac amyloidosis, in particular, if recognized early

66 ty for differentiation of patients with ATTR cardiac amyloidosis (irrespective of genotype) from pati

67 Cardiac amyloidosis is a differential diagnosis in heart

68 Transthyretin-related cardiac amyloidosis is a progressive infiltrative cardio

69 Cardiac amyloidosis is an infiltrative disease with dias

70 Cardiac amyloidosis is associated with characteristic EC

71 Cardiac amyloidosis is characterized by an early impairm

72 After the age of 60, isolated cardiac amyloidosis is four times more common among blac

73 Specific and accurate evaluation of cardiac amyloidosis is now possible using cardiac magnet

74 etin cardiac amyloidosis (also known as ATTR cardiac amyloidosis) is an increasingly recognized cause

75 tics of amyloid fibril formation of three AL cardiac amyloidosis light chains.

76 Manifestations of cardiac amyloidosis may include congestive heart failure

77 resonance was used to exclude patients with cardiac amyloidosis (n = 19).

78 ients with definite amyloid light-chain (AL) cardiac amyloidosis (n=20; 100% with LVH).

79 e analyzed from 1217 patients with suspected cardiac amyloidosis referred for evaluation in specialis

80 ession analyses among participants with ATTR cardiac amyloidosis showed that an H/CL ratio of 1.6 or

81 Patients with primary (AL) cardiac amyloidosis suffer from progressive cardiomyopat

82 r whom there is a high clinical suspicion of cardiac amyloidosis, Tc 99m PYP may be of diagnostic and

83 In patients with cardiac amyloidosis, the pattern of LGE was always typic

84 s a major cause of cardiac dysfunction in AL cardiac amyloidosis, we have previously shown that amylo

85 ture and function and features suggestive of cardiac amyloidosis were assessed in participants who un

86 le method for identifying subjects with ATTR cardiac amyloidosis, which should be studied in a larger

87 We identified 156 patients with cardiac amyloidosis who underwent transesophageal echoca

88 ivity and 92% specificity for detecting ATTR cardiac amyloidosis with an area under the curve of 0.96